Protocol Ledger

NCT06764615 · Phase II · RECRUITING

A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)

Interventional Phase II clinical trial protocol NCT06764615 sponsored by Takeda in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-05-28 Enrollment: 192 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06764615
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)192 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06764615
Protocol FieldVerified Registry Value
NCT IdentifierNCT06764615
Consolidated Lead SponsorTakeda
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment192 participants (ESTIMATED)
Registered Start Date2025-05-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06764615
Hospital Research SiteLocationSite Profile
The Sixth Affiliated Hospital of Sun Yat-sen UniversityGuangzhou, ChinaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Takeda across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI